Zacks Investment Research
09 Jun 2026, 20:36 UTC · 14h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Top 1 mover · tap to explore
What the story claims
3 claims · each scored for market impact
Gilead and Merck's late-stage ISLEND-1 and ISLEND-2 studies for a once-weekly oral HIV treatment met their primary efficacy endpoints. — Positive Phase III data for a potentially first-of-its-kind weekly oral regimen significantly increases the probability of regulatory approval and future revenue.
+0.60The islatravir/lenacapavir regimen demonstrated non-inferior efficacy and a comparable safety profile to current standard-of-care daily therapies. — Establishing non-inferiority against current standards is the critical regulatory hurdle for market entry and adoption.
+0.40Gilead and Merck intend to submit the ISLEND trial data to global regulatory authorities following these results. — Moving toward formal regulatory filing transitions the project from the clinical trial phase to the commercialization pipeline.
+0.30Which stocks this story touches
Continue reading
6 related stories
Announced positive late-stage study data for a new HIV treatment regimen in partnership with Gilead.
Announced positive late-stage study data for a new HIV treatment regimen and reported year-to-date share gains.
Go deeper
You just saw which tickers this one story hits. A free account turns that into a standing screen: the movers delivered on schedule, before the chart catches up.
On this page · free
In the platform
Free account, 30 seconds. No credit card. Covers all 10 tickers this story moves.
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Screener bridge
Catch the names this kind of story moves — before the chart does.
Get the full NIS Momentum results every Friday at 4PM ET — free via email or Telegram.
PRNewsWire
4h ago
